Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.

Thomas, Philip G

Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. [electronic resource] - Transplantation Jun 2007 - 1509-12 p. digital

Publication Type: Journal Article; Randomized Controlled Trial

0041-1337

10.1097/01.tp.0000263344.53000.a1 doi


Adult
Alemtuzumab
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm--adverse effects
Antilymphocyte Serum
Drug Therapy, Combination
Female
Follow-Up Studies
Graft Rejection--epidemiology
Graft Survival
Humans
Immunosuppressive Agents--therapeutic use
Incidence
Kidney Transplantation--mortality
Male
Middle Aged
Mycophenolic Acid--therapeutic use
Risk Factors
Steroids--therapeutic use
Tacrolimus--therapeutic use
Transplantation Tolerance--drug effects